Loading patent…
AssigneesThe Regents of the University of California, The Schepens Eye Research Institute, Inc.
InventorsBenjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Estimating the term…
The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
An eye drop suitable for topical application to an ocular surface comprising:
Dependencies are inferred from the claim text.